This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXMPEB280W7_M.jpg
Westfield Capital Management’s holding in Ironwood Pharmaceuticals, Inc. increased to about 8.5 million shares with the purchase.
Westfield Capital Management first bought Ironwood Pharmaceuticals, Inc. stock in the second quarter of 2018. Westfield Capital Management also owns Bristol-Myers Squibb Co (NYSE:BMY), Thermo Fisher Scientific Inc (NYSE:TMO), Bio-Rad Laboratories Inc (NYSE:BIO) and Blueprint Medicines Corp (NASDAQ:BPMC). Ironwood Pharmaceuticals, Inc. is its number two position by number of shares and market value among biotechnology & life sciences stocks.
Other investors who also added to their Ironwood Pharmaceuticals, Inc. shares include California State Teachers Retirement System, Victory Capital Management, and Gotham Asset Management. In contrast, Fisher Asset Management, Millennium Management, and the T. Rowe Price Equity Income Fund reduced IRWD shares, while Royce & Associates sold all their IRWD shares.
